Maternal Serum Periostin as a Potential Biomarker for Gestational Diabetes Mellitus and Adverse Perinatal Outcomes
Zeitschrift fur Geburtshilfe und Neonatologie, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1055/a-2827-9333
- Dergi Adı: Zeitschrift fur Geburtshilfe und Neonatologie
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Anahtar Kelimeler: biomarker, Gestational diabetes mellitus, periostin, second trimester
- Ondokuz Mayıs Üniversitesi Adresli: Evet
Özet
Objective To investigate whether maternal serum periostin levels measured in the second trimester can serve as a biomarker for gestational diabetes mellitus (GDM) and predict perinatal outcomes. Methods This prospective case-control study included 173 pregnant women (103 with GDM and 70 healthy controls). Serum periostin levels were measured between 15-20 weeks of gestation. GDM was diagnosed using a 75-g oral glucose tolerance test at 24-28 weeks. Receiver operating characteristic (ROC) analysis and logistic regression were used to evaluate diagnostic performance. Results Serum periostin levels were significantly higher in the GDM group compared to controls (median: 50.7 vs. 33.7 ng/mL, p<0.001). Periostin showed moderate diagnostic accuracy for GDM (AUC: 0.752). Higher periostin levels were associated with cesarean delivery, neonatal intensive care unit admission, and meconium-stained amniotic fluid. Conclusion Elevated maternal serum periostin levels in the second trimester are associated with gestational diabetes msellitus and adverse perinatal outcomes. Periostin may serve as a supplementary biomarker for early identification of GDM.